Longitudinal developmental profile of newborns and toddlers treated for spinal muscular atrophy
暂无分享,去创建一个
[1] R. Finkel,et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial , 2022, Nature Medicine.
[2] R. Finkel,et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial , 2022, Nature Medicine.
[3] M. Hiligsmann,et al. Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening , 2022, Developmental medicine and child neurology.
[4] C. Palermo,et al. Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening , 2022, European Journal of Pediatrics.
[5] C. Semenza,et al. Cognitive profiles and clinical factors in type III spinal muscular atrophy: a preliminary study , 2022, Neuromuscular Disorders.
[6] M. Hiligsmann,et al. Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium , 2021, Scientific Reports.
[7] M. Schroth,et al. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go , 2021, Neuromuscular Disorders.
[8] E. Mercuri,et al. Risdiplam in Type 1 Spinal Muscular Atrophy. , 2021, The New England journal of medicine.
[9] G. Baranello,et al. Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1 , 2021, Journal of Neurodevelopmental Disorders.
[10] M. Hiligsmann,et al. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments , 2021, Orphanet Journal of Rare Diseases.
[11] G. Baranello,et al. Brain, cognition, and language development in spinal muscular atrophy type 1: a scoping review , 2021, Developmental medicine and child neurology.
[12] D. Lulé,et al. Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA) , 2021, Orphanet Journal of Rare Diseases.
[13] K. Lidzba,et al. Cognitive and academic profiles in children with cerebral palsy: a narrative review. , 2020, Annals of physical and rehabilitation medicine.
[14] L. Servais,et al. New treatments in spinal muscular atrophy: an overview of currently available data , 2020, Expert opinion on pharmacotherapy.
[15] M. Hiligsmann,et al. 244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10–12, 2019, Hoofdorp, The Netherlands , 2019, Neuromuscular Disorders.
[16] L. Servais,et al. Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives , 2019, Therapeutics and clinical risk management.
[17] R. Finkel,et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study , 2019, Neuromuscular Disorders.
[18] E. Tizzano,et al. Severe brain involvement in 5q spinal muscular atrophy type 0 , 2019, Annals of neurology.
[19] L. Servais,et al. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1 , 2018, Neurology.
[20] F. Aarsen,et al. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain , 2018, Developmental medicine and child neurology.
[21] R. J. Ramamurthi,et al. Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.
[22] Brian K. Kaspar,et al. Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.
[23] Hanns Lochmüller,et al. Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review , 2017, Orphanet Journal of Rare Diseases.
[24] Megan A. Lewis,et al. A Review on Spinal Muscular Atrophy: Awareness, Knowledge, and Attitudes , 2016, Journal of Genetic Counseling.
[25] Kyoko Tanaka,et al. Bayley Scales of Infant and Toddler Development , 2015 .
[26] W. Chung,et al. Spectrum of Neuropathophysiology in Spinal Muscular Atrophy Type I , 2015, Journal of neuropathology and experimental neurology.
[27] F. Aarsen,et al. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy , 2012, Neurology.
[28] J. Ross,et al. SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. , 2010, Human molecular genetics.
[29] A. Meltzoff,et al. Associations between media viewing and language development in children under age 2 years. , 2007, The Journal of pediatrics.
[30] A. Gontard,et al. Behavioural problems in children and adolescents with spinal muscular atrophy and their siblings , 2003, Developmental medicine and child neurology.
[31] Jechil S. Sieratzki,et al. Toddling into language: precocious language development in motor-impaired children with spinal muscular atrophy , 2002 .
[32] A. Gontard,et al. Intelligence and cognitive function in children and adolescents with spinal muscular atrophy , 2002, Neuromuscular Disorders.
[33] J. Melki,et al. The role of the SMN gene in proximal spinal muscular atrophy. , 1998, Human molecular genetics.
[34] P. Patel,et al. Brain atrophy in Werdnig‐Hoffmann disease , 1991, Acta neurologica Scandinavica.
[35] Sato Yoko,et al. Milestones for Communication Development in Japanese Children with Spinal Muscular Atrophy Type I , 2017 .